Clinical Trials › NCT05210621
Active, Not RecruitingPhase 3
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMAB
Sponsored by Centre Hospitalier Universitaire de Nice
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 72
Target enrollment
Mar 2022
Start date
Feb 2029
Expected completion
Interventions / Treatments
Ocrelizumab
Conditions studied
Multiple Sclerosis
Trial locations
U.S. site locations haven't been posted yet for this trial. Check ClinicalTrials.gov for the latest contact and location info.
More Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.